Introduction {#s1}
============

Blebbistatin, an inhibitor of myosin II found by Sellers et al. ([@r1], [@r2]), is known to inhibit not only myosin II ATPase activities of vertebrate striated muscle and non-muscle ([@r2]), but also vertebrate smooth muscle myosin (SMM) ATPase activity ([@r3], [@r4]). Also, blebbistatin at around 10 μM inhibited the contraction of intact smooth muscle preparations and smooth muscle cell ([@r3],[@r4],[@r5],[@r6]). Furthermore, we reported that blebbistatin inhibited the contraction of skinned (cell membrane permeabilized) taenia cecum ([@r7]) and trachea ([@r8]) from the guinea pig without affecting the phosphorylation level of myosin light chain (MLC).

To further analyze the blebbistatin effects on the regulation of actin-myosin interaction in smooth muscle in detail, we examined the effects of the agent on the relaxation processes, composed of fast and slow components, of skinned trachea and taenia cecum of the guinea pig. The slow force decay during relaxation by a Ca^2+^ removal from the medium in skinned smooth muscle is thought to reflect the "latch", originally reported and hypothesized by Dillon et al. ([@r9]), or the latch-like state of smooth muscle ([@r10],[@r11],[@r12],[@r13]). In the present study, effects of blebbistatin on fast and slow (latch-like) cycling bridge are discussed by the kinetic analysis of relaxation processes of skinned trachea and taenia cecum.

A preliminary report of this study was reported as Proceedings of the 22nd annual meeting of Japan Society of Adaptation Medicine ([@r14]).

Materials and Methods {#s2}
=====================

Animal experiments were performed at Tokyo Metropolitan University at Arakawa. All experimental procedures conformed to the "Guidelines for Proper Conduct of Animal Experiments" approved by the Science Council of Japan, and were carried out under the "Rules and Regulations of the Animal Studies Committee of Tokyo Metropolitan University". In addition, Tokyo Metropolitan University approved all procedures involving animals (A27-1, A28-1, A29-1, A30-20). Male Hartley guinea pigs weighing about 250 g were euthanized under deep anesthesia with pentobarbital (Somnopentyl, Kyoritsu Seiyaku Co., Tokyo, Japan). The trachea and the taenia cecum were removed, and immersed in a normal extracellular solution (NES; described below). The trachea and taenia cecum specimens were skinned (cell membarane permeabilized) with 200 μM β-escin (Sigma, St. Louis, MO, USA), and destroyed sarcoplasmic reticulum with 20 μM Ca ionophore A23187 (Sigma) in Relaxing solution (with ATP) for 30 min, then kept in the 50% glycerol at −20° C to prevent freezing of Relaxing solution (with ATP).

A small layer strip of trachea or taenia cecum (0.1--0.2 mm wide and 1.5--2.5 mm long) was prepared by cutting skinned specimen of tracheal cartilage or taenia cecum and stripping connective tissue from the specimen. The skinned preparation was attached to a pair of tungsten wires with silk thread monofilaments, one of which was connected to a force transducer (ULA-10GR, Minebea Mitsumi Inc., Kanagawa, Japan) to measure isometric tension ([@r15]). A bubble plate system with six wells (0.135 ml each) was used to change the solution quickly ([@r16]).

Experimental procedure
----------------------

The skinned preparation was stretched in Relaxing solution (with ATP). After the passive tension reached a steady level (resting tension, up to 10 µN), the preparation was immersed in Ca^2+^-activating solution (with 10^−5^ M Ca^2+^) to elicit the maximal Ca^2+^-induced contraction. When the contractile force reached a maximal steady level, Ca^2+^ was quickly removed in relaxation process with Relaxing solution (with cytidine triphosphate; CTP) for 15 min in the absence or presence of various concentrations of blebbistain to avoid blebbistatin effects on any phosphorylation/dephosphorylation processes ([@r7]), since CTP is a substrate for myosin ATPase, but not for any other kinases ([@r17], [@r18]). For making the rigor conditions in the relaxation process, Rigor solution (without ATP or CTP) was used. In the control, 1% of dimethylsulfoxide (DMSO, Sigma) was added in Relaxing solution (with CTP) or Rigor solution (without ATP or CTP) as a vehicle control.

Solutions and chemicals
-----------------------

NES contained 150 mM NaCl, 4 mM KCl, 2 mM CaCl~2~, 1 mM MgCl~2~, 10 mM glucose, 5 mM 2-\[4-(2-hydroxyethyl)-1-piperazinyl\]ethanesulphonic acid (Nacalai Tesque, Kyoto, Japan), and 50 μU/ml insulin (Sigma), and pH was adjusted with Tris(hydroxymethyl) aminomethane (Tris; Nacalai Tesque) /H~2~O to pH 7.40 at 30 °C. Artificial intracellular solutions for skinned preparations contained 0.85 mM Mg(methanesulfonate)~2~, 1 mM MgATP (1.35 mM total ATP Na~2~, Roche, Indianapolis, IN, USA) or 1 mM MgCTP (1.35 mM total CTPNa, Sigma), 20 mM creatine phosphate Na~2~ (CrP; Nacalai Tesque), 10 mM etylene glycole-bis(2-aminoetyl) tetraacetic acid (EGTA; Nacalai Tesque). K(methanesulfonate) (Nacalai Tesque) was added to the solutions to keep the ionic strength at 200 mM, and pH was adjusted with 20 mM 1,4-piperazinediethanesulophonic acid (PIPES; Nacalai Tesque) and KOH (Wako Pure Chemicals, Osaka, Japan) to 7.0 at 30 °C, which were prepared according to the method of Horiuti ([@r16]). Relxaing solution (with CTP) contained 1 mM MgCTP instead of MgATP. Ca^2+^-activating solution (at 10^-5.0^ M) were prepared by mixing the CaEGTA solution containing 10 mM EGTA and 9.64 mM Ca(methanesulfonate)~2~ with 1µM calmodulin (Wako Pure Chemicals) with the artificial intracellular solution. The apparent dissociation constant of Ca^2+^-EGTA was assumed to be 10^-6.4^ M. Contents of the Rigor solution (without ATP or CTP) were 0.85 mM Mg(methanesulfonate)~2~, 10 mM EGTA. K(methanesulfonate) was added to the solutions to keep the ionic strength at 200 mM, and pH was adjusted with 20 mM PIPES and KOH to 7.0 at 30 °C. Blebbistatin (Toronto Research Chemicals Inc., North York, ON, Canada) was dissolved into DMSO. Major components of the artificial intracellular solutions were noted in [Table 1](#tbl_001){ref-type="table"}Table 1.Major component of the artificial intracellular solutions (mM)Mg^2+^Ca^2+^NucleotideCreatine phosphateRelaxing solution with ATP1.00MgATP 1.020Relaxing solution with CTP1.00MgCTP 1.020Rigor solution1.0000Ca^2+^-activatin solution1.00.01MgATP 1.020.

Data analysis of the mechanical properties
------------------------------------------

The relative tension level of the skinned preparations during relaxation are expressed as below; relative tension = (an observed tension -- the basal tension)/(maximal tension of the Ca^2+^-induced contraction -- the basal tension).

The relaxation process after the Ca^2+^-induced contraction was kinetically analyzed by data fitting to an equation (see below) using the program of Kaleida Graph (Synergy Software, Reading, PA, USA) using the Levenberg-Marquart algorithm;Force(t) = Force(0) × \[e^(-t/τfast)^ + *A*× (1-e^(-t/τfast)^) × (1-e^(-t/τslow-attach)^) × e^(-t/τslow-detatch)^\]---*Formula 1*where Force(0), e^(-t/τfast)^, 1-e^(-t/τfast)^, *A*, 1-e^(-t/τslow-attach)^, and e^(-t/τslow-detatch)^ denote a relative tension level of the test contraction in the absence of blebbistatin, the number of activated cross-bridges, the number of detached cross-bridges, the rate of re-attachment of the detached cross-bridges, the number of attached slow-cycling (latch-like) state, and the number of detached slow cycling state, respectively. See Discussion in detail.

Statistical analysis
--------------------

The results are presented as the mean ± S.E.M. Statistical hypotheses on the differences between means were tested with Student's *t*-test for paired samples unless noted otherwise. The null hypotheses were rejected when *P* was less than 0.05.

Results {#s3}
=======

Effects of blebbistain on the relaxation time course of skinned tracheal and taenia cecum
-----------------------------------------------------------------------------------------

muscle preparation
------------------

When maximally contracting β-escin skinned muscle preparations of guinea pig trachea and taenia caecum with 10^--5.0^ M Ca^2+^ were exposed to Relaxing solution (with CTP) for Ca^2+^ removal, the mechanical force fell gradually with an initial fast phase followed by a slow phase, as typically shown in [Fig. 1](#fig_001){ref-type="fig"}Fig. 1.Typical tension traces of relaxation process after Ca^2+^ removals of β-escin skinned (cell membrane peremiabilized) trachea (A) and taenia cecum (B) preparations in the Relaxing solution (with CTP) with or without blebbistatin at 30 μM, 30.0 ± 1.0 °C. Ordinate: Relative force normalized with the maximal tension level induced by 10^-5.0^ M Ca^2+^ promptly before the Ca^2+^ removal. Abscissa: Time in seonds after the Ca^2+^ removal.. In the trachea, the removal of Ca^2+^ elicited a rapid relaxation with a latency of less than a few seconds followd by a gradual relaxation during 900 sec observation time ([Fig. 1A](#fig_001){ref-type="fig"}). In the taenia, the removal of Ca^2+^ elicited a prompt relaxation, and the rate of relaxation was apparently bigger and the level of relaxation reached in the observation time was lower, when compared with those of the trachea ([Fig. 1B](#fig_001){ref-type="fig"}). The presence of blebbistatin (30 μM) apparently accelerated relaxations of the trachea and taenia, and the relative amount of relaxation was bigger in the taenia (more than 90% of the maximum tension) than in the trachea (about 80%) in the presence of blebbistatin ([Fig. 1A and B](#fig_001){ref-type="fig"}).

[Figure 2](#fig_002){ref-type="fig"}Fig. 2.Statistical representation for the effects of blebbistatin on the relaxation processes of β-escin skinned tracheal smooth muscle (A) and skinned taenia cecum (B) in the presence of CTP. Control (filled circles), and blebbistatin at 10 μM (open triangles) and 30 μM (filled squares). Symbols and associated bars are means and ± S.E.M., respectively, n=11. \*Significant difference of the force compared with that of control, where *P*\<0.05. shows the statistical representation for the Ca^2+^ removal-induced relaxation processes of the trachea ([Fig. 2A](#fig_002){ref-type="fig"}) and taenia ([Fig. 2B](#fig_002){ref-type="fig"}) in the absence and presence of blebbistatin (10 or 30 μM). Apparently, the initial relaxation phase after removal of Ca^2+^ was slower in the trachea than in the taenia, and the relaxed level during 900 sec was higher in the trachea than in the taenia. The presence of blebbistatin (30 μM, but not 10 μM) in the relaxing solution significantly augmented the relaxation process of the trachea at time \>700 sec after Ca^2+^-removal. In the taenia, blebbistatin 10 and 30 μM significantly elicited the augmentation of relaxation; significant differences were observed at time \>300 sec at 10 μM and at time \>40 sec after Ca^2+^-removal at 30 μM.

Effects of blebbistatin on relaxation-process in the rigor condition
--------------------------------------------------------------------

[Figure 3](#fig_003){ref-type="fig"}Fig. 3.Effects of blebbistatin on the relaxation processes of β-escin skinned tracheal smooth muscle (A) and skinned taenia cecum (B) in the absence of nucleotide (Rigor condition). Control (filled circles), and blebbistatin at 10 μM (open triangles) and 30 μM (filled squares). Symbols and associated bars are means and ± S.E.M., respectively, n=11. \*Significant difference from the control (*P*\<0.05). shows the effects of blebbistatin on the relaxation process in the absence of nucleotide in Rigor solution (without ATP or CTP). In the rigor conditions, relaxation processes of the trachea and taenia after Ca^2+^-removal apparently impeded. Compared with the normal CTP-contained conditions, the initial phase of relaxation was inhibited both in the trachea and taenia. The terminal relaxation level in the rigor conditions during observation time was not much different from the normal conditions in the trachea, but was much higher in the taenia.

The presence of blebbistatin (10 and 30 μM) did not have significant effects on the relaxation process in Rigor solution (without CTP) both in the skinned trachea ([Fig. 3A](#fig_003){ref-type="fig"}) and taenia cecum ([Fig. 3B](#fig_003){ref-type="fig"}).

Data fitting analysis
---------------------

Relaxation processes of fast and slow phases in skinned preparations of trachea and taenia cecum were well fitted with the equation of Formula-1, considering with parameters of three constants for fast detaching (τfast-detach), slow attaching (τslow-attach) and slow detaching crossbridges (τslow-detach), and rate of re-attachment of detached crossbridges (*A*) (see Materials and Methods).

In control conditions with CTP, τfast-detach (47.7 sec) and *A* (0.618) of trachea were 2.5 and 3.6 times bigger than those of taenia, respectively, and other parameters were similar between trachea and taenia ([Table 2](#tbl_002){ref-type="table"}Table 2.Kinetic parameters of τfast-detach, τslow-attach, τslow-detach, and *A* obtained from relaxation processes of the skinned preparations of trachea and taeinia cecum of the guinea pig in Relaxing solution (with CTP) with or without blebbistatin 30 μMTracheaTaenia cecumControl30 μMControl30 μMτfast-detach (sec)47.7 ± 5.5679.3 ± 26.519.0 ± 2.2817.0 ± 1.50τslow-attach (sec)59.6 ± 36.151.9 ± 14.855.3 ± 15.567.0 ± 36.4τslow-detach (sec)1,830 ± 413774 ± 218 \*2,000 ± 3431,060 ± 239\**A*0.618 ± 0.0570.536 ± 0.0970.168 ± 0.0260.092 ± 0.018\*Values represent mean ± S.E.M. (trachea n=11, taenia cecum n=8). \**P*\<0.05.Parameters of τ fast-detach, τslow-attach, τslow-detach and *A* represent the rate constants of fastly detaching, slowly attaching and slow detaching crossbridges, and the rate of re-attachment of detached crossbridges, in order.), reflecting the slow and rapid relaxations of the trachea and taenia, respectively. The presence of blebbistatin (30 μM) with CTP significantly reduced τslow-detach to 2/5 and 1/2 of control in the trachea and taenia, respectively ([Table 2](#tbl_002){ref-type="table"}), which represents the accerelation of detachment process in the slow (latch-like) bridges cycling. The presence of blebbistatin in Relaxing solution (with CTP) elicited a significant reduction in *A* value by 1/2 of control in the taenia, but a marginable and insignificant reduction in the trachea ([Table 2](#tbl_002){ref-type="table"}).

[Table 3](#tbl_003){ref-type="table"}Table 3.Effect of blebbistatin on τfast-detach, τrigor-attach, τrigor-detach, and *A* in the absence of nucleotide in Rigor solutionTracheaTaenia cecumControl30 μMControl30 μMτfast-detach (sec)78.0 ± 13.1126 ± 16.635.2 ± 4.5339.4 ± 8.59τrigor-attach (sec)42.4 ± 4.0046.3 ± 8.1524.7 ± 7.5534.2 ± 9.16τrigor-detach (sec)1,500 ± 3803,590 ± 14.7\*1,250 ± 161.6980 ± 140*A*0.648 ± 0.0500.526 ± 0.089\*0.450 ± 0.0440.381 ± 0.070Values represent mean ± S.E.M. (trachea n=11, taenia cecum n=8). \**P*\<0.05.In addition to parameters listed on [Table 2](#tbl_002){ref-type="table"}, τrigor-attach and τrigor-detach represent time sonstants of attaching and detaching rigor-bridge in the rigor conditions. shows the effects of blebbistatin (30 μM) on kinetic parameters for relaxation of skinned muscles in Rigor solution (without ATP or CTP). In the trachea, the presence of blebbistatin prolonged τfast-detach 1.6 folds of control, just as much fold as that in Rexaxing solution (with CTP). In contrast to the reduction of τslow-detach in Rexaxing solution (with CTP), blebbestatin in Rigor solution elicited an increase in τrigor-detach 2.4 folds of control in the trachea. Values of τrigor-attach and *A* of the trachea were not much affected by the presence of blebbistatin, being similar as in the normal solution. In the taenia exposed to Rigor solution, blebbistatin elicited marginal and insignificant effects on all parameters tested: small reduction in mean values of τrigor-detach and a (both 0.8 folds of control). Briefly, the presence of blebbisttin in Rigor solution elicited the prolongation in τrigor-detach in the trachea, but tended to marginally elicit the accerelation in τrigor-detach and the inhibition in re-attachment of crossbridges in the taenia.

Discussion {#s4}
==========

The present study showed that in β-escin skinned tracheal and taenia cecum smooth muscle preparations from guinea pigs, blebbistatin significantly accelerated relaxation process by Ca^2+^ removal after the Ca^2+^-induced active tension development.

Before discussing the mechanisms of the accelerating effects of blebbistatin on the relaxation, we will note the adequacy of data fitting of the regression analysis. We previously proposed that a portion of Ca^2+^-calmodulin-activated fast crossbridges do not dissociate rapidly following dephosphorylation of myosin light chain by Ca^2+^ removal, but are transferred to latch-bridges ([@r12], [@r13]) that dissociate very slowly. Consequently, the observed time course of the force change during relaxation was well fitted with an equation that includes two time constants for the fast detaching crossbridges and the latch-bridges ([@r11]), as given below;Force~(~*~t~*~)~ = Force**~(0)~** × \[(1 -- *A*) × e^(-^*^t^*^/τ(fast))^ + *A* × e ^(-^*^t^*^/τ(latch)^ ) *---Formula 2*where *t* is time after Ca^2+^ removal, τ(fast) and τ(latch) are time constants of the fast detaching crossbridges and the latch-bridges respectively, *A* is the fraction of the crossbridges transferred from the fast detaching crossbridges to the latch-bridges, Force~(~*~t~*~)~ is the relative force at *t* sec after the Ca^2+^ removal. Since the dissociation rate of fast detaching crossbridges is linearly related to the rate of MLC dephosphorylation, τ(fast) is expressed as a function of time constant of MLC dephosphorylation \[τ(MLC-D)\] as τ(fast) = k ×τ(MLC-D) *---Formula 3*,where k is a constant of complex reactions other than MLC dephosphorylation during fast detaching crossbridges.

However, we observed that the initial force decay followed by a small force increment shortly, then a very slow force decrement was observed in some skinned preparations (data not shown), so *Formula 2* is difficult to explain the observation. Therefore, we now propose that a number of detached fast crossbridges reattached then slowly detached described as *Formula 1* to explain the small force increment after the initial force decay. Since the regression analysis using the *Formula 1* fits the time course of the present data almost precisely, we suggest that the *Formula 1* is adequate to explain the relaxation process of the skinned smooth muscle.

The regression analysis shows that acceleration of relaxation process by blebbistatin is due to accelerate detachment of slow cycling (latch-like) bridges, but not to alteration in detachment of the fast cycling crossbridges both in skinned trachea and taenia cecum ([Table 2](#tbl_002){ref-type="table"}). Blebbistatin binds at the apex of the 50 kDa cleft of the skeletal myosin head of myosin-ADP-Pi complex and interferes with the phosphate release process, resulting that the inhibitor blocks myosin in an actin-detached state, and therefore it prevents rigid actomyosin cross-linking in skeletal muscle myosin ([@r1], [@r2]). Also, the molecule stabilizes the helical order of myosin filaments of striated muscles ([@r19]). In smooth muscle, we previously found that blebbistatin suppressed the force development independent of Ca^2+^ sensitivity for the force and MLC phosphorylation level in β escin skinned taenia cecum ([@r7]) and trachea ([@r8]), and conformational changes in SMM ([@r7]), and these results indicates direct inhibition of actin-myosin interaction through modulation of SMM ATPase activity and/or SMM structure by blebbistatin. Therefore, the present result that blebbistatin had little effects on detachment of fast cycling crossbridge (τfast-detach in [Table 2](#tbl_002){ref-type="table"}) supports our previous conclusion ([@r7], [@r8]), since the detachment of the fast cycling crossbridge depends on the dephosphorylation of MLC (13, *Formula 3*), and also the previous evidence that blebbistatin might not act after phosphate release from SMM ([@r1], [@r2]).

Our present results also indicate that blebbistatin acts slow cycling (latch-like) bridges as accelerating dissociation (τslow-detach in [Table 2](#tbl_002){ref-type="table"}). Blebbistatin is known to bind with neither nucleotide-binding pocket of myosin-head nor actin binding site, and causes a conformational changes of lever arm domain of myosin head by binding to MgADPPi bound state of myosin ([@r20]). Therefore, blebbistatin induced acceleration of slow cycling (latch-like) bridge dissociation might result from not only inhibiting myosin ATPase activity, but changes in myosin orientation by conformational change of myosin head. In fact, ATPase activity is much lower of slow cycling (latch) bridges than that of fast cycling crossbridges, indicating that contribution of SMM ATPase inhibition seems to be relatively little in blebbistatin induced acceleration of slow cycling (latch-like) bridge dissociation. Interestingly, blebbistatin decreased the rate of re-attachment ("*A*" in [Table 2](#tbl_002){ref-type="table"}) only in skinned taenia cecum, but not in skinned trachea. Differences of factors such as cooperativity between trachea and taenia cecum may determine the rate "*A*", which contributes to the different susceptibility of blebbistatin effects on the slow cycling (latch-like) bridge formation. In particular, contractility of tracheal and colonic smooth muscle is characterized as "tonic" and "phasic", respectively ([@r21]), suggesting that the differences of regulatory mechanisms between "tonic" and "phasic" smooth muscle might contribute the differences of the blebbistatin effects. In other words, blebbistatin may be a tool for classifying smooth muscle into phasic and tonic muscles.

As shown in [Fig. 3](#fig_003){ref-type="fig"}, Ca^2+^ removal caused a slow force decay even in the absence of nucleotides (rigor state). Our results support conclusions of previous studies that the axial motion of smooth muscle bound to actin upon dissociation of MgADP was not associated with (rigor) force generation ([@r22]), and MgADP release rate of SMM is about 20 times slower than that of skeletal myosin ([@r22]).

Blebbistatin had little effects on the force decay in the absence of nucleotide in Rigor solution (without ATP or CTP) in skinned taenia cecum, and this observation is consistent with binding characteristics of blebbistatin with myosin ([@r1]). On the other hand, in skinned trachea, the kinetic analysis suggests that the agent suppresses both formation and deformation of rigor-bridge ([Table 3](#tbl_003){ref-type="table"}). Although difference of nucleotide release rate between skinned trachea and taenia cecum in Rigor solution (without ATP or CTP) causes the divergences of the results, further studies are necessary for the mechanisms of blebbistatin effects on smooth muscle in the absence of nucleotides.

It should be also noted that blebbistatin suppresses not only SMM activity, but also non-muscle myosin (NMM) activity in tracheal muscle, and the agent attenuates tracheal muscle contraction through inhibiting formation of membrane adhesome complexes which mediate force transmission and regulate cortical actin polymerization ([@r23]). In fact, blebbistatin inhibits translocation of protein kinase C (PKC) ζ to cell membrane through suppression of NMM activity in myotube ([@r24]). Therefore, blebbistatin-induced NMM inhibition modulates PKC activity which accelerate relaxation process in skinned smooth muscle, since PP2A inhibition suppresses contraction of basilar artery through PKC mediated MLC thiophosphorylation ([@r25]). However, as described in Materials and Methods, we measured the relaxation process using Relaxing solution (with CTP) to avoid blebbistatin effects on any phosphorylation/dephosphorylation processes ([@r7]), since CTP is a substrate for myosin ATPase, but not for any other kinases ([@r17], [@r18]). Thus, contribution of any phosphorylation/dephorphorylation processes during relaxation process in the present study seems to be negligible.

In conclusion, blebbistatin accelerates relaxation process of skinned smooth muscle by affecting slow cycling (latch-like) bridge formation and/or its dissociation. Since regulatory mechanisms of slow cycling (latch-like) bridge are still unclear, blebbistatin is a useful tool in investigating slow cycling (latch-like) bridge in detail.
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